sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks TP-10

TP-10

CAS No.:
898563-00-3
Catalog Number:
AG00GU9K
Molecular Formula:
C26H19F3N4O
Molecular Weight:
460.4505
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
98%
1 week
United States
$640
- +
10mg
98%
1 week
United States
$890
- +
50mg
98%
1 week
United States
$2557
- +
100mg
98%
1 week
United States
$3557
- +
Product Description
Catalog Number:
AG00GU9K
Chemical Name:
TP-10
CAS Number:
898563-00-3
Molecular Formula:
C26H19F3N4O
Molecular Weight:
460.4505
MDL Number:
MFCD17167072
IUPAC Name:
2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline
InChI:
InChI=1S/C26H19F3N4O/c27-26(28,29)17-33-15-23(18-11-13-30-14-12-18)25(32-33)20-6-9-22(10-7-20)34-16-21-8-5-19-3-1-2-4-24(19)31-21/h1-15H,16-17H2
InChI Key:
NOIXNOMHHWGUTG-UHFFFAOYSA-N
SMILES:
FC(Cn1nc(c(c1)c1ccncc1)c1ccc(cc1)OCc1ccc2c(n1)cccc2)(F)F
Properties
Complexity:
636  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
460.151g/mol
Formal Charge:
0
Heavy Atom Count:
34  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
460.46g/mol
Monoisotopic Mass:
460.151g/mol
Rotatable Bond Count:
6  
Topological Polar Surface Area:
52.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
5.3  
Literature
Title Journal
Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors. Bioorganic & medicinal chemistry letters 20120301
Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A. European journal of medicinal chemistry 20110901
Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease. The Journal of pharmacology and experimental therapeutics 20110101
Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PloS one 20100101
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. Journal of medicinal chemistry 20090827
Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. The Journal of pharmacology and experimental therapeutics 20080501
Properties